(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 2.61% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 2.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Johnson & Johnson's revenue in 2023 is $96,041,000,000.On average, 6 Wall Street analysts forecast JNJ's revenue for 2023 to be $255,688,640,241,361, with the lowest JNJ revenue forecast at $254,514,750,174,236, and the highest JNJ revenue forecast at $256,506,986,682,770. On average, 6 Wall Street analysts forecast JNJ's revenue for 2024 to be $263,423,767,777,556, with the lowest JNJ revenue forecast at $259,926,417,502,693, and the highest JNJ revenue forecast at $266,032,070,745,309.
In 2025, JNJ is forecast to generate $271,427,844,627,919 in revenue, with the lowest revenue forecast at $271,427,844,627,919 and the highest revenue forecast at $271,427,844,627,919.